Terms: = Brain cancer AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874
3512 results:
1. Rapid detection of idh mutations in gliomas by intraoperative mass spectrometry.
Hua W; Zhang W; Brown H; Wu J; Fang X; Shahi M; Chen R; Zhang H; Jiao B; Wang N; Xu H; Fu M; Wang X; Zhang J; Zhang X; Wang Q; Zhu W; Ye D; Garcia DM; Chaichana K; Cooks RG; Ouyang Z; Mao Y; Quinones-Hinojosa A
Proc Natl Acad Sci U S A; 2024 Jun; 121(23):e2318843121. PubMed ID: 38805277
[TBL] [Abstract] [Full Text] [Related]
2. 7 Tesla magnetic resonance spectroscopic imaging predicting idh status and glioma grading.
Cadrien C; Sharma S; Lazen P; Licandro R; Furtner J; Lipka A; Niess E; Hingerl L; Motyka S; Gruber S; Strasser B; Kiesel B; Mischkulnig M; Preusser M; Roetzer-Pejrimovsky T; Wöhrer A; Weber M; Dorfer C; Trattnig S; Rössler K; Bogner W; Widhalm G; Hangel G
Cancer Imaging; 2024 May; 24(1):67. PubMed ID: 38802883
[TBL] [Abstract] [Full Text] [Related]
3. Evaluation of the rapid Idylla idh1-2 mutation assay in FFPE glioma samples.
Solomon JP; Munoz-Zuluaga C; Slocum C; Dillard A; Cong L; Wang J; Lindeman N; Kluk M; Liechty B; Pisapia D; Rennert H; Velu PD
Diagn Pathol; 2024 May; 19(1):70. PubMed ID: 38796421
[TBL] [Abstract] [Full Text] [Related]
4. Cellular signaling in glioblastoma: A molecular and clinical perspective.
Ghosh D; Pryor B; Jiang N
Int Rev Cell Mol Biol; 2024; 386():1-47. PubMed ID: 38782497
[TBL] [Abstract] [Full Text] [Related]
5. Pediatric high grade gliomas: A comprehensive histopathological, immunohistochemical and molecular integrated approach in routine practice.
Das S; Ahlawat S; Panda AK; Sarangi J; Jain P; Gupta RK; Vaishya S; Patir R
Pathol Res Pract; 2024 Jun; 258():155347. PubMed ID: 38763090
[TBL] [Abstract] [Full Text] [Related]
6. Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management.
Rosas-Alonso R; Colmenarejo-Fernández J; Pernía O; Burdiel M; Rodríguez-Antolín C; Losantos-García I; Rubio T; Moreno-Velasco R; Esteban-Rodríguez I; Martínez-Marín V; Yubero P; Costa-Fraga N; Díaz-Lagares A; López-López R; Díaz-Martin E; García JF; Sánchez CV; Gandía-González ML; Moreno-Bueno G; de Castro J; de Cáceres II
Sci Rep; 2024 May; 14(1):11398. PubMed ID: 38762534
[TBL] [Abstract] [Full Text] [Related]
7. A longer time to relapse is associated with a larger increase in differences between paired primary and recurrent idh wild-type glioblastomas at both the transcriptomic and genomic levels.
Ho WM; Chen CY; Chiang TW; Chuang TJ
Acta Neuropathol Commun; 2024 May; 12(1):77. PubMed ID: 38762464
[TBL] [Abstract] [Full Text] [Related]
8. idh1 mutation produces R-2-hydroxyglutarate (R-2HG) and induces mir-182-5p expression to regulate cell cycle and tumor formation in glioma.
Zhao H; Meng L; Du P; Liao X; Mo X; Gong M; Chen J; Liao Y
Biol Res; 2024 May; 57(1):30. PubMed ID: 38760850
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic relevance of radiological findings on early postoperative MRI for 187 consecutive glioblastoma patients receiving standard therapy.
Rykkje AM; Carlsen JF; Larsen VA; Skjøth-Rasmussen J; Christensen IJ; Nielsen MB; Poulsen HS; Urup TH; Hansen AE
Sci Rep; 2024 May; 14(1):10985. PubMed ID: 38744979
[TBL] [Abstract] [Full Text] [Related]
10. Transformation of idh-wildtype glioblastoma to gliosarcoma with features of osteosarcoma.
Sobczyk P; Sobstyl M; Acewicz A; Rosa J; Grabiec M; Grajkowska W
Folia Neuropathol; 2024; 62(1):96-101. PubMed ID: 38741436
[TBL] [Abstract] [Full Text] [Related]
11. Association of 5-aminolevulinic acid fluorescence guided resection with photodynamic therapy in recurrent glioblastoma: a matched cohort study.
da Silva EB; Vasquez MWM; de Almeida Teixeira BC; Neto MC; Sprenger F; Filho JLN; Almeida-Lopes L; Ramina R
Acta Neurochir (Wien); 2024 May; 166(1):212. PubMed ID: 38739282
[TBL] [Abstract] [Full Text] [Related]
12. IL-6 significantly correlated with the prognosis in low-grade glioma and the mediating effect of immune microenvironment.
Yang SD; Chen MZ; Yang DF; Hu SB; Zheng DD
Medicine (Baltimore); 2024 May; 103(19):e38091. PubMed ID: 38728467
[TBL] [Abstract] [Full Text] [Related]
13. Glioma.
Weller M; Wen PY; Chang SM; Dirven L; Lim M; Monje M; Reifenberger G
Nat Rev Dis Primers; 2024 May; 10(1):33. PubMed ID: 38724526
[TBL] [Abstract] [Full Text] [Related]
14. State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.
Schaff LR; Ioannou M; Geurts M; van den Bent MJ; Mellinghoff IK; Schreck KC
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e431450. PubMed ID: 38723228
[TBL] [Abstract] [Full Text] [Related]
15. Differential tractography and whole brain connectometry in primary motor area gliomas resection: A feasibility study.
Figueredo LF; Mejía-Cordovez JA; Gomez-Amarillo DA; Hakim F; Pimienta-Redondo HD; Almeida JP; Kehayov I; Angelova P; Apostolov G; Luzzi S; Baldoncini M; Johnson JM; Ordóñez-Rubiano EG
Clin Neurol Neurosurg; 2024 Jun; 241():108305. PubMed ID: 38713964
[TBL] [Abstract] [Full Text] [Related]
16. MRI Scoring Systems for Predicting Isocitrate Dehydrogenase Mutation and Chromosome 1p/19q Codeletion in Adult-type Diffuse Glioma Lacking Contrast Enhancement.
Kang KM; Song J; Choi Y; Park C; Park JE; Kim HS; Park SH; Park CK; Choi SH
Radiology; 2024 May; 311(2):e233120. PubMed ID: 38713025
[TBL] [Abstract] [Full Text] [Related]
17. Comprehensive analysis of the REST transcription factor regulatory networks in idh mutant and idh wild-type glioma cell lines and tumors.
Perycz M; Dabrowski MJ; Jardanowska-Kotuniak M; Roura AJ; Gielniewski B; Stepniak K; Dramiński M; Ciechomska IA; Kaminska B; Wojtas B
Acta Neuropathol Commun; 2024 May; 12(1):72. PubMed ID: 38711090
[TBL] [Abstract] [Full Text] [Related]
18. Diffuse infiltrating tumour with the molecular profile of an atypical teratoid rhabdoid tumour (AT/RT SHH-1B) in an adult patient.
Cordier F; Schouten JW; Geurts M; Kros JM; Dubbink HJ; Verlinden V; Federico A; Kool M; Maas SLN
Neuropathol Appl Neurobiol; 2024 Jun; 50(3):e12983. PubMed ID: 38708554
[TBL] [Abstract] [Full Text] [Related]
19. Structural- and DTI- MRI enable automated prediction of idh Mutation Status in CNS WHO Grade 2-4 glioma patients: a deep Radiomics Approach.
Yuan J; Siakallis L; Li HB; Brandner S; Zhang J; Li C; Mancini L; Bisdas S
BMC Med Imaging; 2024 May; 24(1):104. PubMed ID: 38702613
[TBL] [Abstract] [Full Text] [Related]
20. Case report: Temozolomide induced hypermutation indicates an unfavorable response to immunotherapy in patient with gliomas.
Liu J; Hu S; Jiang H; Cui Y
Front Immunol; 2024; 15():1369972. PubMed ID: 38690285
[TBL] [Abstract] [Full Text] [Related]
[Next]
